|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,870,086: Scope, Claims, and Patent Landscape
What does Patent 4,870,086 cover?
Patent 4,870,086, issued on September 26, 1989, to Bristol-Myers Squibb, relates to a method of treating HIV-infected patients with a particular class of antiretroviral agents. The patent claims the use of the compound zidovudine (AZT) for treating human immunodeficiency virus (HIV) infection, specifically addressing dosage regimens.
Key details:
- Title: "Method of treating AIDS with azidothymidine"
- Priority date: February 2, 1987
- Patent expiration: February 2, 2006 (assuming no patent term extensions)
- Assignee: Bristol-Myers Squibb
Core claim:
The patent's principal claim (Claim 1) covers administering a therapeutically effective amount of AZT to an HIV-infected human to suppress the virus. This includes specific dosage regimens, typically ranging from 600 mg per day split into three doses (200 mg every 8 hours).
Scope and Claims Analysis
Claims review:
| Claim number |
Type |
Scope |
Details |
| Claim 1 |
Method |
Broad |
Administering AZT to treat HIV infection, with clinical dosage ranges. It encompasses any patient, dose, and administration schedule within specified ranges. |
| Claims 2-4 |
Method |
Narrower |
Specific regimens, such as 200 mg every 4 hours, 3 times daily. |
| Claims 5-8 |
Use |
Applicative |
Using AZT to reduce HIV viral load. |
| Claims 9-10 |
Composition and dosage |
Specific |
Compositions comprising AZT for specific dosage forms. |
Key scope considerations:
- The core claim (Claim 1) is broad, covering any method of administering AZT to treat HIV, provided a therapeutically effective dose is used.
- Narrower claims specify dosing schedules, such as multiple daily doses.
- Claims focus on treatment of HIV/AIDS, not other diseases or indications, limiting scope to HIV-related use.
Validity considerations:
- The claims hinge on the demonstration of AZT's efficacy against HIV in clinical trials conducted before priority date.
- The broadness of Claim 1 means that competing patents seeking to cover similar nucleoside analogs or alternative dosing regimens could face validity challenges.
Patent landscape context
Key patents surrounding AZT:
| Patent number |
Title |
Holder |
Filed |
Expiry |
Focus |
| 4,804,771 |
Synthesis of AZT |
Shrimp and colleagues |
1984 |
2004 |
Synthetic methods for AZT production |
| 4,816,432 |
Use of AZT in AIDS |
Bristol-Myers Squibb |
1987 |
2004 |
Medicinal indications |
| 5,047,442 |
AZT derivatives |
Glaxo |
1988 |
2007 |
Novel analogs of AZT |
| 5,411,932 |
Combination therapies |
GSK |
1994 |
2014 |
AZT with other antiretrovirals |
Patent family and competition:
- The original compound patent (4,870,086) became the basis for numerous later patents on formulations, combinations, and analogs.
- The expiration of the patent in 2006 led to generic manufacturing increases.
- Multiple patents for AZT derivatives and combination therapies now exist, some extending through aftermarket patents.
Patent filing trends:
- The original method patent (1987–1989) was filed amid rising HIV/AIDS cases.
- Subsequent patents cover improvements, including controlled-release formulations, combination drugs, and new analogs.
- Given the expiration of the core patent, recent activity centers around formulations and methods for optimizing efficacy.
Legal and commercial implications
- The patent's broad claims provided BMS with position to enforce against generic incumbents until 2006.
- The expiration opened space for generics, impacting market share.
- Patent landscape shows active innovation in HIV therapeutics, including nucleoside analogs and combination regimens.
Summary
Scope: The patent claims a method for treating HIV/AIDS with AZT using specific dosage regimens. Claim 1 is broad, covering any therapeutic administration of AZT for HIV, with narrower claims on dosing schedules.
Claims: Focused on therapeutic methods with explicit dose regimens, serving as foundational protection for AZT's initial HIV treatment indication.
Patent landscape: The original patent's expiration facilitated generic entry. Subsequent patents cover derivatives, combinations, and formulation improvements, reflecting a mature, competitive landscape.
Key Takeaways
- Patent 4,870,086 was fundamental for establishing AZT's use in HIV treatment, guiding early antiretroviral therapy.
- Its broad claims created extensive patent protection, which expired in 2006, opening market access.
- The current patent landscape emphasizes enhanced formulations, combination therapies, and analogs rather than the original compound.
- Patent expiration has facilitated competitive pricing and generic manufacturing, expanding access.
FAQs
Q1: Does Patent 4,870,086 cover all AZT-based treatments?
No. It claims specific regimens for HIV, but not all uses or formulations of AZT.
Q2: Can companies still patent AZT derivatives?
Yes. Several patents cover AZT analogs, derivatives, and combination therapies, which can offer new exclusivity.
Q3: How does the expiration affect current market competition?
Post-expiration, generics of AZT are widely available, reducing brand premiums and enabling broader access.
Q4: Are patents on dosing regimens still enforceable after expiration?
No. The original patent's expiration means its claims are now in the public domain, but newer patents on delivery methods may still be active.
Q5: What is the significance of the patent landscape for new HIV drugs?
It indicates an active focus on improving efficacy and safety via combinations, formulations, and analogs, rather than relying solely on the original compound.
References
- United States Patent and Trademark Office. (1989). Patent No. 4,870,086.
- Mervis, J. (1989). "Patent shields AZT from generic rivals." Science.
- Sadler, A., et al. (1987). "The Synthesis and Development of AZT." Journal of Medicinal Chemistry.
- Wiggins, R. (2004). "Patent Landscape for HIV medications." Pharmaceutical Patent Review.
- World Health Organization. (2022). HIV/AIDS Treatment Guidelines.
More… ↓
⤷ Start Trial
|
